Leveraging Large-Scale Genetics of PTSD and Cardiovascular Disease to Demonstrate Robust Shared Risk and Improve Risk Prediction Accuracy
Publication: American Journal of Psychiatry
CME has expired
Abstract
Objective:
Individuals with posttraumatic stress disorder (PTSD) are significantly more likely to be diagnosed with cardiovascular disease (CVD) (e.g., myocardial infarction, stroke). The evidence for this link is so compelling that the National Institutes of Health convened a working group to determine gaps in the literature, including the need for large-scale genomic studies to identify shared genetic risk. The aim of the present study was to address some of these gaps by utilizing PTSD and CVD genome-wide association study (GWAS) summary statistics in a large biobank sample to determine the shared genetic risk of PTSD and CVD.
Methods:
A large health care biobank data set was used (N=36,412), combined with GWAS summary statistics from publicly available large-scale PTSD and CVD studies. Disease phenotypes (e.g., PTSD) were collected from electronic health records. De-identified genetic data from the biobank were genotyped using Illumina SNP array. Summary statistics data sets were processed with the following quality-control criteria: 1) SNP heritability h2 >0.05, 2) compute z-statistics (z=beta/SE or z=log(OR)/SE), 3) filter nonvariable SNPs (0<freq<1), and 4) filter SNPs with low number of samples. The multitrait analysis of GWAS (MTAG) approach was used to combine GWAS summary statistics.
Results:
Significant genetic correlations were found between PTSD and CVD (rG=0.24, SE=0.06), and Mendelian randomization analyses indicated a potential causal link from PTSD to hypertension (β=0.20, SE=0.04), but not the reverse. PTSD summary statistics significantly predicted PTSD diagnostic status (R2=0.27), and this was significantly improved by incorporating summary statistics from CVD and major depressive disorder (R2=1.30). Further, pathway enrichment analyses indicated that genetic variants involved in shared PTSD-CVD risk included those involved in postsynaptic structure, synapse organization, and interleukin-7-mediated signaling pathways.
Conclusions:
The results from this study suggest that PTSD and CVD may share genetic risk. Further, these results implicate PTSD as a risk factor leading to the development of hypertension and coronary artery disease. Additional research is needed to determine the clinical utility of these findings.
Cardiovascular disease (CVD) is the leading cause of death in the United States, affecting over 650,000 people each year (1). Rates of CVD and hypertension are even higher among individuals who have experienced trauma, and particularly those with posttraumatic stress disorder (PTSD) (2, 3). PTSD is a highly impairing psychiatric condition with symptoms such as intrusions, avoidance of trauma-related stimuli, negative alterations in cognition and mood, and hyperarousal (4). PTSD is often characterized by an exaggerated fear response controlled by the sympathetic nervous system. It is thought that chronic activation of this system strains the cardiovascular and immune systems, ultimately increasing susceptibility to CVD (5). Despite the epidemiological evidence linking PTSD and CVD, there remain significant gaps with regard to how PTSD and CVD interact to confer risk in trauma-exposed individuals.
Given the preponderance of evidence supporting a PTSD-CVD link, the National Heart, Lung, and Blood Institute (NHLBI) convened a working group entitled “The Cardiovascular Consequences of Posttraumatic Stress Disorder,” which brought together experts from the NHLBI and the American Heart Association to determine research gaps and priorities (6). As reviewed by O’Donnell et al. (7), there are several gaps related to the genetics of PTSD and CVD: 1) “lack of large-scale datasets with deep genetic data and both PTSD and CVD measures”; 2) “lack of population cohort studies and biobanks to harness genetics and genomics to understand shared risks of PTSD and CVD”; and 3) “lack of polygenic risk scores from genome-wide association studies (GWASs) of PTSD and CVD to inform potential causal PTSD-CVD associations and identify potential therapeutic targets.” Addressing these gaps will improve PTSD and CVD risk identification, which can be used to improve PTSD treatment and reduce concurrent CVD risk. While there is still much to be done to address these gaps, the PTSD and CVD genetics fields have made significant advances with the advent of new technologies and more international collaboration.
Recent PTSD genetic studies have primarily taken a GWAS approach, catapulted by the creation of the PTSD division of the Psychiatric Genomics Consortium (PGC-PTSD) (8). The first GWAS analyses in PTSD identified several risk genes and single-nucleotide polymorphisms (SNPs), including the rs8042149 SNP (9), the Tolloid-like 1 gene (10), lincRNA AC068718.1 (11), the PRTFDC1 gene (12), and the rs717947 SNP (8, 13). In the first PGC-PTSD study, Duncan et al. (14) found significant genetic overlap between PTSD and schizophrenia, and recent work identified sex- and ancestry-based differences in PTSD heritability (15). The PTSD GWAS summary statistics from the PGC-PTSD have also been used to create polygenic risk scores (PRSs) that predict PTSD in large independent cohorts of veterans (15, 16). Given the heterogeneity of PTSD and its polygenic nature, PRS studies using PGC-PTSD summary statistics will be crucial to improving our prediction of PTSD risk.
The field of CVD genetics has seen similar advances in terms of utilizing large samples across research groups. The Coronary Artery Disease Genome-Wide Replication and Meta-Analysis (CARDIoGRAM) consortium is comparable to the PGC-PTSD in that it was developed to allow for significantly larger studies with more power to detect genetic contributions to coronary artery disease (CAD; the largest subset of CVD) (17). The consortium initially conducted a meta-analysis of GWASs and identified 13 risk loci for CAD, and several follow-up studies confirmed most of these and found evidence for additional loci implicating genes involved in vascular function (e.g., PECAM1, PROCR) (18–20). GWAS has also been used to identify genetic risk for other aspects of CVD and its risk factors, such as blood pressure (21), stroke (22), atrial fibrillation (23), carotid intima media thickness and carotid plaque (i.e., subclinical atherosclerosis) (24), and heart failure (25).
Three studies have reported on the shared genetics of PTSD and CVD. Using a candidate gene approach, Pollard et al. (26) found that 37 PTSD risk genes relevant to immune function and inflammation were also independent risk genes for CVD. Sumner et al. (27) used the PGC-PTSD GWAS summary statistics (12) and found evidence for genetic overlap of PTSD and CAD, but these results did not survive correction for multiple testing. In a subsequent study, Sumner et al. (28) used PGC-PTSD GWAS summary statistics and found significant main effects of PTSD symptoms for blood pressure in a trans-ethnic meta-analysis, although there was heterogeneity in the results. Given these promising findings, additional large-scale genetic analyses are needed to better account for the shared heritability of PTSD and CVD, and to improve genetic prediction. Further, it is critical to consider major depressive disorder (MDD) because it is highly comorbid with PTSD (29), and like PTSD, it carries a significant risk of CVD (30). Thus, genetic risk studies will be enhanced by considering PTSD, MDD, and CVD as inherently linked disorders.
The present study addresses gaps in the PTSD-CVD genetics literature as identified by the NHLBI working group (6). We utilized a large-scale health care biobank data set (N=36,412) that contains CVD, PTSD, and MDD diagnostic data, as well as both PTSD and CVD GWAS summary statistics that included 1.3 million samples. Our goals were 1) to test genetic correlations between PTSD/MDD and CVD, and to estimate their magnitudes using current GWAS summary statistics data; 2) to leverage these relationships to improve genetic prediction performances; and 3) to identify the shared biological pathways or genes underlying the genetic correlations.
Methods
Participants and Procedure
This study included 36,412 participants from the Mass General Brigham Biobank (MGBB), which is a biorepository of Mass General Brigham Healthcare (e.g., Massachusetts General Hospital, McLean Hospital). Participants provide blood samples, complete health surveys, and consent to these being linked to clinical data from electronic health records (EHRs). This study included the subset of MGBB participants whose blood samples had been genotyped as of April 2020. PTSD diagnosis was determined based on the presence of at least one ICD-10 code in a patient’s EHR (i.e., based on clinical judgment). Hypertension and depression phenotypes were determined using “curated disease populations” determined using algorithms developed by the MGBB to increase phenotype accuracy (see the online supplement) (31, 32). Cardiovascular disease subphenotypes of congestive heart failure and ischemic stroke were also determined through curated disease populations, and myocardial infarction was determined based on the presence of at least one ICD-10 code. Pulse and average systolic and diastolic blood pressure were also collected from EHR data through the MGBB. Averages were determined from all of the measures of these vital signs available in individual health histories. Therefore, the number of collections included in the average differs for each patient. See Table 1 for more information.
| Characteristic | PTSD | No PTSD | Overall | |||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| Sex | ||||||
| Female | 1,459 | 67.90 | 18,253 | 53.30 | 19,712 | 54.10 |
| Male | 689 | 32.10 | 16,009 | 46.70 | 16,698 | 45.90 |
| Predicted ancestry | ||||||
| African | 267 | 12.40 | 2,144 | 6.30 | 2,411 | 6.60 |
| East Asian | 21 | 1.00 | 525 | 1.50 | 546 | 1.50 |
| European | 1,658 | 77.20 | 30,092 | 87.80 | 31,750 | 87.20 |
| South Asian | 202 | 9.40 | 1,501 | 4.40 | 1,703 | 4.70 |
| Major depression | ||||||
| Case subjects | 1,133 | 52.70 | 5,034 | 14.70 | 6,167 | 16.90 |
| Control subjects | 1,015 | 47.30 | 29,228 | 85.30 | 30,243 | 83.10 |
| Coronary artery disease | ||||||
| Case subjects | 121 | 5.60 | 3,604 | 10.50 | 3,725 | 10.20 |
| Control subjects | 2,027 | 94.40 | 30,658 | 89.50 | 32,685 | 89.80 |
| Hypertension | ||||||
| Case subjects | 910 | 42.40 | 15,198 | 44.40 | 16,108 | 44.20 |
| Control subjects | 1,238 | 57.60 | 19,064 | 55.60 | 20,302 | 55.80 |
| Mean | SD | Mean | SD | Mean | SD | |
| Age (years) | 50.5 | 15.3 | 60.4 | 17 | 59.8 | 17.1 |
| Pulse | 81.4 | 10.5 | 75.7 | 10.7 | 76 | 10.7 |
| Blood pressure (mmHg) | ||||||
| Systolic | 123 | 11.1 | 127 | 12.4 | 126 | 12.4 |
| Diastolic | 75.3 | 7.07 | 75.1 | 7.32 | 75.1 | 7.31 |
a
PTSD=posttraumatic stress disorder.
Genetic Data
See Figure 1 for an overview of the genetic analysis procedure. Briefly, de-identified genetic data were requested from the MGBB and were genotyped using Illumina SNP array. Quality control was performed on each batch individually and the batches were merged, resulting in a total of 36,422 individuals and 9,036,179 variants after imputation. Ancestry prediction was performed using a classification model trained on 1,000 Genomes samples (39). Most participants included in the summary statistics are of European ancestry (>87%). To minimize the effect of population stratification, only those genetically predicted to have European ancestry (N=31,634) were included for further analysis. Self-identified and predicted ancestry sample sizes are listed in Table S1 in the online supplement.
FIGURE 1. Workflow of data acquisition, processing, and analysisa
aCAD=coronary artery disease; CVD=cardiovascular disease; CVT=cardiovascular traits; GWAS=genome-wide association study; HWE=Hardy-Weinberg equilibrium; LDSC=linkage disequilibrium score regression; MAF=minor allele frequency; MDD=major depressive disorder; MTAG=multitrait analysis of GWAS; PC=principal component; PRS=polygenic risk score; PTSD=posttraumatic stress disorder; QC=quality control; SNP=single-nucleotide polymorphism.
GWAS Summary Statistics Data
Publicly available GWAS summary statistics from several recent publications on PTSD, MDD, and CVD were collected. Summary statistics data sets were processed with the following quality control criteria: 1) SNP heritability h2 >0.05; 2) compute z-statistics (z=beta/SE or z=log(OR)/SE); 3) filter nonvariable SNPs (0<freq<1); and 4) filter SNPs with low number of samples. Five summary statistics survived the quality control criteria and were used for further analysis: 1) ptsd_eur_freeze2: the PGC-PTSD freeze-2 (15); 2) PGC_MDD2018_ex23andMe: the latest result from PGC-MDD excluding the 23andMe samples (33); 3) UKBB_broad_Depression: UK Biobank (UKBB) analysis for depression phenotypes (34); and large-scale genetic studies for 4) UKBB_Essential_Hypertension: hypertension (35), and 5) CAD_Nikpay: CAD (19). More detail on summary statistics is provided in Table S2 in the online supplement.
For proprietary reasons, the PGC-MDD summary statistics that included the 23andMe samples are not publicly available. Therefore, we only used summary statistics conducted without the 23andMe cohort. With UKBB, summary statistics on three depression phenotypes were provided: probable MDD, ICD-defined MDD, and broad depression (defined by a self-reported help-seeking history for problems related to anxiety and depression) (34). Only broad depression resulted in a SNP heritability estimate greater than 5%. Therefore, only broad depression summary statistics were included for further analysis.
GWAS and SNP Heritability Estimates on MGBB Data
We conducted a GWAS for four diseases: PTSD, MDD, hypertension, and CAD. A quantitative GWAS was also conducted for quantitative cardiovascular traits (average, minimum, and maximum pulse rate; systolic and diastolic blood pressure). Approximately 6 million variants were tested. Only variants on the 22 autosomal chromosomes were considered. To control for population stratification, the first 10 principal components were included as covariates. Age, sex, and batch were included as additional covariates. The analysis was performed using PLINK-2 (36).
Combining Summary Statistics and Estimating Genetic Correlations
The multitrait analysis of GWAS (MTAG) approach was used to combine GWAS summary statistics (37). MTAG is a generalization of inverse-variance weighted meta-analyses of summary statistics. However, unlike standard meta-analysis, MTAG computes trait-specific association analysis for each individual trait. Summary statistics for PTSD, MDD, hypertension, and CAD were incorporated.
Linkage disequilibrium (LD) score regression (LDSC) was used to estimate genetic correlations (38). LDSC is a Python-based command line tool for estimating genetic correlations and SNP heritability from GWAS summary statistics. Precomputed LD scores for European ancestry from the 1,000 Genomes Project were used (39). Genetic correlations were computed among individual summary statistics as well as among meta-analysis summary statistics for the four phenotypes (PTSD, MDD, hypertension, and CAD).
Constructing and Evaluating Polygenic Risk Score
PRS was computed as a weighted sum of the additively coded number of risk/effect alleles (0 for homozygous non-risk genotype, 1 for heterozygous genotype, and 2 for homozygous risk genotype). The weights were the beta or odds ratio from univariate test statistics obtained from the summary statistics of previous individual GWASs or with combined summary statistics using MTAG. Owing to methodological advantage (in particular, not requiring individual-level training genetic data), LD clumping followed by p-value thresholding is the popular way of selecting variants included in the score. The LD clumping step was done on a window of 250 kb and squared correlation of allele counts of 0.1. In the p-value thresholding step, PRS was computed for several thresholds. The optimal threshold is determined based on prediction performance as assessed by Nagelkerke’s R2 (a pseudo R2 for binary variables). Nagelkerke’s R2 was computed as the difference of its value in the full model (which contains the PRS and covariates) and in the null model (which contains only the covariates). This is done for each of the PRSs independently. See Figure S1 in the online supplement for results of the thresholding step. PRS analysis was conducted using PRSice-2 (40), including age, sex, and the first 10 ancestry-related principal components as covariates.
To determine the prediction power of PRS, additional performance metrics were evaluated. Area under the receiver operating characteristic curve (AUC) was computed with the pROC package in R (41). Binary disease labels along with quantitative PRS values were used. To further evaluate the discriminatory ability of MTAG-PRS, stratification performance of the PRS was computed. This was done by binning samples into equal-sized risk strata based on PRS values. Next, disease incidence rate and odds ratio were computed for each risk group. For odds ratio, the first (the least-risk group) was used as the reference.
Mendelian Randomization
Mendelian randomization was used to test the causal link between PTSD and CVD (see the online supplement for more information). Using two-stage least-squares regression, PTSD and MDD were our two exposure variables and hypertension and CAD were the two outcome variables, and the same models were tested in reverse with hypertension and CAD as the exposure variables and PTSD and MDD as the outcome variables (i.e., eight models tested). In the first stage, the exposure (binary PTSD or MDD label) is regressed against PTSD/MDD PRS and control variables (age and the first five principal components). Using this regression model, the predicted value of the exposure is computed. In the second stage, the outcome variable (binary hypertension or CAD label) is regressed against the predicted exposure variable and control variables. Next, epidemiological causality is inferred based on the significance of the coefficient of the predicted exposure variable.
Pathway Analysis
Pathway analysis was performed using FUMA (42). FUMA is a web-based application that annotates a set of given variants from GWAS summary statistics by utilizing information from 18 data repositories and tools. It was implemented in two main analysis steps. In the first step (SNP2GENE), after taking a set of input variants, it added variants that were in linkage disequilibrium with the input significant variants, and SNPs were annotated (with biological functionality) and mapped to genes (with positional, eQTL, and chromatin interaction mapping). In the second step (GENE2FUNC), the set of prioritized genes from the first step were annotated with biological functions and mechanisms. This included enrichment in biological pathways and functional categories. Adjusted p values with Benjamini-Hochberg false discovery rate correction for multiple testing were computed.
Results
In the total sample, 2,149 participants were PTSD-positive case subjects and 34,269 were PTSD-negative control subjects. In terms of depression, 6,167 participants were predicted to have current MDD or a past history of MDD (of these, 1,133 had comorbid PTSD), while the remaining 30,243 were MDD negative. See Table 1 for additional phenotypes and quantitative data by PTSD status.
Genetic Correlations Between PTSD and CVD
Genetic correlations were estimated in two ways. First, estimates were calculated using individual GWAS summary statistics (both publicly available as well as from new MGBB GWAS analysis). Then, large-scale meta-analysis summary statistics were computed by combining publicly available as well as the MGBB summary statistics for each of the four disease labels of primary interest. The four meta-analyses were PTSD (N=183,000): MGBB GWAS+PGC-PTSD freeze-2; MDD (N=362,584): MGBB GWAS+PGC-MDD+UKBB_ICD_MDD; hypertension (N=440,089): MGBB GWAS+UKBB_Essential_Hypertension; and CAD (N=217,000): MGBB GWAS+Nikpay_CAD. Using both of these approaches, statistically significant genetic correlations were estimated between PTSD and hypertension/CAD. With the meta-analysis summary statistics, PTSD demonstrated a significant positive genetic correlation with hypertension (rG=0.35, SE=0.06, p=9.45E−10) and CAD (rG=0.24, SE=0.06, p=5.09E−5). Similarly, MDD demonstrated significant genetic correlations with hypertension (rG=0.31, SE=0.03, p=4.73E−33) as well as CAD (rG=0.18, SE=0.03, p=8.99E−9). Genetic correlation estimates between PTSD/MDD and hypertension/CAD are listed in Table 2.
| MDD_meta | Hypertension_meta | CAD_meta | |||||||
|---|---|---|---|---|---|---|---|---|---|
| rG | SE | p | rG | SE | p | rG | SE | p | |
| PTSD_meta | 0.81 | 0.073 | 1.75E−28 | 0.35 | 0.057 | 9.45E−10 | 0.24 | 0.060 | 5.09E−5 |
| MDD_meta | 0.31 | 0.026 | 4.73E−33 | 0.18 | 0.032 | 8.99E−9 | |||
| Hypertension_meta | 0.62 | 0.028 | 8.06E−111 | ||||||
a
The table lists correlation results using meta-analyzed summary statistics (e.g., MDD_meta includes all MDD samples along with our MGBB sample). CAD=coronary artery disease; CVD=cardiovascular disease; MDD=major depressive disorder; PTSD=posttraumatic stress disorder.
Improving Genetic Prediction of PTSD
Next, we sought to leverage these robust correlations to improve the genetic prediction performances for PTSD diagnosis. First, we combined only publicly available summary statistics using MTAG. The MGBB samples were not included in the base/training summary statistics, which were used as the target/testing data set. As depicted in Table 3 and Figure 2, incorporating summary statistics for MDD and CVD resulted in improvement of both stratification and the discrimination ability of the PRS, such that the prediction of PTSD diagnosis was significantly enhanced. Using only PGC-PTSD freeze-2 summary statistics resulted in an AUC of 0.546 (95% CI=0.532, 0.560), while using summary statistics that combined PTSD, MDD, hypertension, and CAD resulted in an AUC of 0.592 (95% CI=0.578, 0.606). See Figure S2 in the online supplement for hypertension and CAD prediction performance.
| Base Summary Statistics | Target Phenotype | PRS R2 | p | p Threshold | No. of SNPs |
|---|---|---|---|---|---|
| PTSD-freeze-2 | PTSD | 0.27 | 5.31E−8 | 0.4237 | 35,485 |
| PTSD-CVD | PTSD | 0.26 | 1.36E−7 | 0.3493 | 31,256 |
| PTSD-MDD | PTSD | 1.23 | 8.05E−31 | 0.0253 | 5,019 |
| PTSD-MDD-CVD | PTSD | 1.30 | 2.16E−32 | 0.0776 | 11,162 |
a
CVD=cardiovascular disease; MDD=major depressive disorder; PRS=polygenic risk score; PTSD=posttraumatic stress disorder; SNP=single-nucleotide polymorphism.
FIGURE 2. Stratification and discrimination ability of the polygenic risk score constructed with various summary statisticsa
aPanel A shows odds ratios of PTSD diagnosis in PRS-stratified risk groups; the first risk group is used as the reference. Panel B shows the fraction of participants diagnosed with PTSD in risk groups stratified into deciles (using PTSD, MDD, and CVD summary statistics). Panel C shows the fraction of participants diagnosed with PTSD in risk groups stratified into quintiles (using PTSD, MDD, and CVD summary statistics). Panel D shows the discrimination ability of the various PRSs as measured by AUC, with greatest AUC for PTSD+MDD+CVD summary statistics. AUC=area under the curve; CVD=cardiovascular disease; MDD=major depressive disorder; PRS=polygenic risk score; PTSD=posttraumatic stress disorder.
Mendelian Randomization to Determine Causal PTSD-CVD Link
Given that eight models were tested, we used a Bonferroni-corrected p value of 0.00625 (0.05/8). All of the models with PTSD and MDD predicting hypertension and CAD were significant using this threshold: PTSD predicting hypertension (β=0.20, SE=0.04, p=5.97E−6), PTSD predicting CAD (β=0.22, SE=0.07, p=9.22E−4), MDD predicting hypertension (β=0.43, SE=0.10, p=5.97E−6), and MDD predicting CAD (β=0.47, SE=0.14, p=9.22E−4). Of the models in the reverse direction, only the model with CAD predicting PTSD was significant, but barely over the threshold of p<0.00625 (β=0.31, SE=0.11, p=0.0041). See Table S4 in the online supplement for a summary of all eight models. Overall, these findings provide greater support for a causal link in the direction from psychiatric disorders to hypertension and CAD, but not the reverse.
Pathway Enrichment Analysis With Shared Genetic Variants
A set of genetic variants at the significance threshold of p<1.0E−5 (for MTAG-combined GWAS results with MGBB along with base summary statistics that combined PGC-PTSD, UKBB-depression, hypertension, and CAD) were used to perform pathway annotation and functional analysis with FUMA. This p-value threshold was used to include more genes and variants for pathway analysis, which is a common practice for these analyses (43). In the first step, SNP2GENE, the set of variants are mapped to genes based on genetic coordinates. The 87 genomic risk loci included in the pathway analysis are shown in Figure S3 in the online supplement. The 8,734 SNPs falling in these genomic risk loci are mapped to 198 genes. In the second step, GENE2FUNC, the prioritized genes are used as input to the second step to perform functional annotation. Top significantly enriched gene ontology biological processes in the set of genes included those involved in the regulation of postsynaptic structure (p=0.00001, padj=0.005), synapse organization (p=0.0001, padj=0.02), and interleukin-7 (IL-7)–mediated signaling pathways (p=0.0002, padj=0.03). In addition to the pathways, tissue specificity was assessed using differentially expressed genes (comparing a given tissue label with all other labels). However, no statistically significant result was found (see Figure S4 in the online supplement).
Discussion
This is the first study to examine the shared genetic susceptibility of PTSD and CVD utilizing large-scale genome-wide cross-trait analysis from both PTSD and CVD GWAS summary statistics, which were derived from a total of 1.3 million samples, and 31,758 genotyped samples that were used as the target/test data set. We identified significant genetic correlations between PTSD and CVD, as well as MDD, and Mendelian randomization analyses provided support for a causal link from PTSD to hypertension and CAD, but not the reverse. We were also able to significantly improve the genetic prediction of PTSD by incorporating summary statistics from CVD and MDD. Further, pathway enrichment analyses indicated that genetic variants involved in shared PTSD-CVD risk included those involved in postsynaptic structure, synapse organization, and immune function. These findings suggest that PTSD and CVD risk identification may be improved by their mutual consideration, which can be used to improve PTSD treatment selection.
A preponderance of epidemiological data has suggested that individuals with PTSD are more likely to experience CVD (2, 3). As identified by the NHLBI working group (6) on PTSD-CVD risk, large-scale studies are needed to better understand the shared genetic risk of these diseases. Here, we provide the first evidence of shared genetic risk for PTSD and CVD using summary statistics from both literatures. We also found significant genetic associations of PTSD and CVD with MDD, which is consistent with previous research supporting comorbidity of MDD with both PTSD and CVD (29). While the overlap of mental disorders is increasingly accepted in psychiatry (44), our results suggest that two highly impairing psychiatric conditions also overlap with a set of cardiovascular diagnoses thought to have more discrete origins. This provides further evidence that psychiatric and physical health conditions are not only common in phenotypic presentation, but they are also genetically linked.
Our Mendelian randomization analyses found evidence that genetic risk for PTSD and MDD exerted a causal effect on hypertension and CAD risk. One of the primary mechanisms implicated in the link between PTSD/MDD and CVD is elevated sympathetic arousal that leads to hypertension, both directly (i.e., chronically elevated blood pressure due to stress) and via the renin-angiotensin system (i.e., elevated blood pressure due to renin and angiotensin-II release that causes vasoconstriction). Our findings provide support for this mechanism, but we cannot exclude the possibility that confounding factors or mediating effects (e.g., diet, smoking) are responsible for these associations, which should be examined in future research. Our pathway enrichment analyses suggested that genetic variants involved in postsynaptic structure, synapse organization, and immune function (IL-7) may be relevant to the shared genetic risk of PTSD and CVD. While IL-7 has not previously been studied in the context of PTSD, other immune markers and genes (e.g., IL-6, IL-8) have been implicated in PTSD, and it has been suggested that impaired immune function may be a mechanism underlying the PTSD-CVD link (5, 26). Given that IL-7 has been implicated in hypertension and atherosclerosis (45, 46), this further implicates the role of immune function in the shared genetic risk of PTSD and CVD, and it suggests that additional study of these genetic variants is warranted.
The primary clinical implication of this work is improved risk identification, which can be used to enhance PTSD treatment and decrease CVD risk. For example, identifying individuals with shared PTSD and CVD risk (and knowing that PTSD is a specific risk factor for CVD) will allow clinicians to select PTSD interventions that are known to improve aspects of cardiovascular function. There is preliminary evidence that forms of cognitive-behavioral therapy (the first-line treatment for PTSD) improve cardiovascular function (47), but this research is still in its early stages. On the other hand, psychiatric and CVD medications have well-documented effects on cardiovascular function (48, 49), but few studies have tested the effects of these medications on subsequent CVD risk in PTSD populations. Medications targeting the renin-angiotensin system (e.g., ACE inhibitors, beta-blockers) have demonstrated efficacy in rodent models, but research in humans with PTSD has been mixed (50, 51). A next step in this line of work is to determine whether existing cognitive-behavioral and pharmacological treatments actually reduce CVD risk in PTSD, and to determine whether they are more efficacious for individuals with high genetic risk for both PTSD and CVD. An additional and more immediate next step is to include PTSD as an indicator of CVD risk in routine care (e.g., during hypertension screening).
While our use of a large biobank sample is a strength of this study, it also has inherent limitations. For example, PTSD diagnosis was based on single ICD-10 codes, which were not necessarily the result of standardized assessments (e.g., the Clinician-Administered PTSD Scale [52]). This approach, while necessary for large-scale data analyses, is not as reliable as using clinician-administered assessments of PTSD, as we cannot determine whether some PTSD diagnoses were given incorrectly. Another limitation is that the MGBB sample comprises primarily White, non-Hispanic individuals. As a result, over 87% of participants were of European ancestry, and analyses were conducted only on these individuals. While this approach minimized the effect of population stratification, it means that our findings may not replicate to other racial/ethnic/ancestry groups. Finally, it is important to note that the relationship between PTSD and CVD is likely mediated, at least in part, by behavioral risk factors, such as diet, exercise, smoking, and alcohol/substance use. These risk factors are independently associated with CVD risk and cardiometabolic diseases that are linked with CVD (e.g., type 2 diabetes). Thus, a limitation of this study is the lack of data on these behavioral variables that likely influence the pathways through which PTSD may lead to CVD. Research using multivariate Mendelian randomization approaches is needed to further assess the role of possible confounding or mediating factors in the PTSD-CVD link. Similarly, it will be critical for future studies to test whether the PTSD and MDD correlations with CAD depend on hypertension, and whether PTSD and MDD each has unique risk associated with hypertension and CAD independent of the other.
The link between PTSD and CVD has been well established from an epidemiological standpoint. As identified by the 2018 NHLBI working group (6), large-scale genetic studies are needed to improve characterization of PTSD and CVD risk, which will subsequently improve risk management and treatment. We directly addressed some of these needs by utilizing a large biobank sample (N=36,412) and by leveraging large-scale GWAS summary statistics from both the PTSD and CVD literatures with 1.3 million samples. Our results indicate that 1) there is substantial genetic overlap between PTSD and CVD, 2) PTSD and MDD may be risk factors leading to the development of hypertension and CAD, and 3) the genetic prediction of PTSD risk is improved by the consideration of polygenic risk for CVD and MDD. Future studies of genetic risk and diagnostic prediction would benefit from incorporating this polygenic risk approach.
Footnote
Drs. Seligowski and Misganaw share first authorship.
Supplementary Material
File (appi.ajp.21111113.ds001.pdf)
- View/Download
- 663.67 KB
File (appi.ajp.21111113.ds002.figss5-s22.pdf)
- View/Download
- 7.40 MB
References
1.
Centers for Disease Control and Prevention: Heart Disease Facts. 2021. https://www.cdc.gov/heartdisease/facts.htm
2.
Edmondson D, Kronish IM, Shaffer JA, et al: Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J 2013; 166:806–814
3.
Edmondson D, von Känel R: Post-traumatic stress disorder and cardiovascular disease. Lancet Psychiatry 2017; 4:320–329
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC, American Psychiatric Publishing, 2013
5.
Michopoulos V, Vester A, Neigh G: Posttraumatic stress disorder: a metabolic disorder in disguise? Exp Neurol 2016; 284:220–229
6.
NHLBI Working Group: The cardiovascular consequences of post-traumatic stress disorder. NIH: National Heart, Lung, and Blood Institute, November 13–14, 2018. https://www.nhlbi.nih.gov/events/2018/nhlbi-working-group-cardiovascular-consequences-post-traumatic-stress-disorder
7.
O’Donnell CJ, Longacre LS, Cohen BE: Posttraumatic stress disorder and cardiovascular disease: state of the science, knowledge gaps, and research opportunities. JAMA Cardiol 2021; 6:1207–1216
8.
Nievergelt CM, Ashley-Koch AE, Dalvie S, et al: Genomic approaches to posttraumatic stress disorder: the Psychiatric Genomic Consortium Initiative. Biol Psychiatry 2018; 83:831–839
9.
Logue MW, Baldwin C, Guffanti G, et al: A genome-wide association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus. Mol Psychiatry 2013; 18:937–942
10.
Xie P, Kranzler HR, Yang C, et al: Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder. Biol Psychiatry 2013; 74:656–663
11.
Guffanti G, Galea S, Yan L, et al: Genome-wide association study implicates a novel RNA gene, the lincRNA AC068718.1, as a risk factor for post-traumatic stress disorder in women. Psychoneuroendocrinology 2013; 38:3029–3038
12.
Nievergelt CM, Maihofer AX, Mustapic M, et al: Genomic predictors of combat stress vulnerability and resilience in US Marines: a genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology 2015; 51:459–471
13.
Almli LM, Stevens JS, Smith AK, et al: A genome-wide identified risk variant for PTSD is a methylation quantitative trait locus and confers decreased cortical activation to fearful faces. Am J Med Genet B Neuropsychiatr Genet 2015; 168B:327–336
14.
Duncan LE, Ratanatharathorn A, Aiello AE, et al: Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. Mol Psychiatry 2018; 23:666–673
15.
Nievergelt CM, Maihofer AX, Klengel T, et al: International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun 2019; 10:4558
16.
Gelernter J, Sun N, Polimanti R, et al: Genome-wide association study of post-traumatic stress disorder reexperiencing symptoms in >165,000 US veterans. Nat Neurosci 2019; 22:1394–1401
17.
Schunkert H, König IR, Kathiresan S, et al: Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43:333–338
18.
CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, et al: Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45:25–33
19.
Nikpay M, Goel A, Won HH, et al: A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015; 47:1121–1130
20.
Howson JMM, Zhao W, Barnes DR, et al: Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nat Genet 2017; 49:1113–1119
21.
Franceschini N, Fox E, Zhang Z, et al: Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. Am J Hum Genet 2013; 93:545–554
22.
Malik R, Chauhan G, Traylor M, et al: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2018; 50:524–537
23.
Roselli C, Chaffin MD, Weng LC, et al: Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet 2018; 50:1225–1233
24.
Franceschini N, Giambartolomei C, de Vries PS, et al: GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nat Commun 2018; 9:5141
25.
Aragam KG, Chaffin M, Levinson RT, et al: Phenotypic refinement of heart failure in a national biobank facilitates genetic discovery. Circulation (Online ahead of print, November 11, 2018)
26.
Pollard HB, Shivakumar C, Starr J, et al: “Soldier’s heart”: a genetic basis for elevated cardiovascular disease risk associated with post-traumatic stress disorder. Front Mol Neurosci 2016; 9:87
27.
Sumner JA, Duncan LE, Wolf EJ, et al: Letter to the editor: Posttraumatic stress disorder has genetic overlap with cardiometabolic traits. Psychol Med 2017; 47:2036–2039
28.
Sumner JA, Maihofer AX, Michopoulos V, et al: Examining individual and synergistic contributions of PTSD and genetics to blood pressure: a trans-ethnic meta-analysis. Front Neurosci 2021; 15:678503
29.
Rytwinski NK, Scur MD, Feeny NC, et al: The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: a meta-analysis. J Trauma Stress 2013; 26:299–309
30.
Penninx BWJH: Depression and cardiovascular disease: epidemiological evidence on their linking mechanisms. Neurosci Biobehav Rev 2017; 74:277–286
31.
McCoy TH, Castro VM, Snapper LA, et al: Efficient genome-wide association in biobanks using topic modeling identifies multiple novel disease loci. Mol Med 2017; 23:285–294
32.
McCoy TH, Castro VM, Hart KL, et al: Genome-wide association study of dimensional psychopathology using electronic health records. Biol Psychiatry 2018; 83:1005–1011
33.
Wray NR, Ripke S, Mattheisen M, et al: Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018; 50:668–681
34.
Howard DM, Adams MJ, Shirali M, et al: Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun 2018; 9:1470
35.
Bi W, Fritsche LG, Mukherjee B, et al: A fast and accurate method for genome-wide time-to-event data analysis and its application to UK Biobank. Am J Hum Genet 2020; 107:222–233
36.
Chang CC, Chow CC, Tellier LC, et al: Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4:7
37.
Turley P, Walters RK, Maghzian O, et al: Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat Genet 2018; 50:229–237
38.
Bulik-Sullivan BK, Loh PR, Finucane HK, et al: LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet 2015; 47:291–295
39.
1000 Genomes Project Consortium, Auton A, Brooks LD, et al: A global reference for human genetic variation. Nature 2015; 526:68–74
40.
Choi SW, O-Reilly PF: PRSice-2: polygenic risk score software for biobank-scale data. Gigascience 2019; 8:giz082
41.
Robin X, Turck N, Hainard A, et al: pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12:77
42.
Watanabe K, Taskesen E, van Bochoven A, et al: Functional mapping and annotation of genetic associations with FUMA. Nat Commun 2017; 8:1826
43.
Savage JE, Jansen PR, Stringer S, et al: Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet 2018; 50:912–919
44.
Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62:617–627
45.
Crouch SH, Botha-Le Roux S, Delles C, et al: Inflammation and hypertension development: a longitudinal analysis of the African-PREDICT study. Int J Cardiol Hypertens 2020; 7:100067
46.
Jalkanen J, Hollmén M, Maksimow M, et al: Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine 2019; 114:74–80
47.
Bourassa KJ, Hendrickson RC, Reger GM, et al: Posttraumatic stress disorder treatment effects on cardiovascular physiology: a systematic review and agenda for future research. J Trauma Stress 2021; 34:384–393
48.
Steckler T, Risbrough V: Pharmacological treatment of PTSD: established and new approaches. Neuropharmacology 2012; 62:617–627
49.
Raskind MA, Peskind ER, Chow B, et al: Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med 2018; 378:507–517
50.
Marvar PJ, Goodman J, Fuchs S, et al: Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. Biol Psychiatry 2014; 75:864–872
51.
Stein MB, Jain S, Simon NM, et al: Randomized, placebo-controlled trial of the angiotensin receptor antagonist losartan for posttraumatic stress disorder. Biol Psychiatry 2021; 90:473–481
52.
Weathers FW, Bovin MJ, Lee DJ, et al: The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess 2018; 30:383–395
Information & Authors
Information
Published In
History
Received: 9 November 2021
Revision received: 15 February 2022
Revision received: 10 May 2022
Accepted: 26 May 2022
Published online: 7 September 2022
Published in print: November 01, 2022
Keywords
Authors
Competing Interests
Dr. Ressler has served as a consultant for Acer, Alkermes, Bionomics, BioXcel, Jazz Pharma, and Takeda; he has received research support from Alto Neuroscience, BrainsWay, Genomind, NIH, and Takeda; and he has served on scientific advisory boards for the Brain Research Foundation, Janssen, Sage, and Verily. The other authors report no financial relationships with commercial interests.
Funding Information
Dr. Seligowski was supported by NIH grant K23MH125920-01 and American Heart Association grant 20CDA35310031. Dr. Ressler was supported by NIH grants R21MH112956, P50MH115874, R01MH094757, and R01MH106595 and the Frazier Foundation Grant for Mood and Anxiety Research. The authors acknowledge the Mass General Brigham Biobank for providing genomic data and health information data.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).